Cardiorenal benefits of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes without cardiovascular and renal diseases

Diabetes Obes Metab. 2022 Mar;24(3):575-577. doi: 10.1111/dom.14588. Epub 2021 Nov 15.

Authors

Mei Qiu¹, Xian Zhou², Miao Zhang³

Affiliations

¹ Department of General Medicine, Shenzhen Longhua District Central Hospital, Shenzhen, China.
² Department of General Medicine, Yan'an Hospital Affiliated to Kunming Medical University, Kunming, China.
³ Department of Nephrology, Shenzhen Hospital of Beijing University of Chinese Medicine, Shenzhen, China.

PMID: 34729884
DOI: 10.1111/dom.14588

No abstract available

Keywords: CVRD-free; DPP4i; SGLT2i; cardiovascular; death; renal; type 2 diabetes.

Publication types

Letter

MeSH terms

Cardiovascular Diseases* / prevention & control
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Dipeptidyl-Peptidase IV Inhibitors* / therapeutic use
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
Glucose
Humans
Hypoglycemic Agents / therapeutic use
Sodium
Sodium-Glucose Transporter 2 Inhibitors* / therapeutic use
Symporters*

Substances

Dipeptidyl-Peptidase IV Inhibitors
Hypoglycemic Agents
Sodium-Glucose Transporter 2 Inhibitors
Symporters
Sodium
Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
Glucose